Study Summary:
A multicenter, randomized, double-blind, placebo-controlled, 8-week study to evaluate the safety and efficacy of Nebivolol and Valsartan given as a fixed-dose combination in patients with stage 1 or 2 essential Hypertension.
Qualified Participants Must:
• Be 18 years of age and older
•
Have hypertension (high blood Pressure)
•
Not be pregnant
•
Not have Type 1 Diabetes
•
Be able to attend 15 clinic Visits in approximately 16 weeks
Qualified Participants May Receive:
Study related medical care and study medication at no cost and compensation for time and travel.
Health insurance is not necessary